609
Participants
Start Date
June 30, 2014
Primary Completion Date
May 26, 2017
Study Completion Date
May 26, 2017
Erenumab
Administered by subcutaneous injection once a month
Research Site, Sandvika
Research Site, Glostrup Municipality
Research Site, Lillehammer
Research Site, Stavanger
Research Site, Ålesund
Research Site, Berlin
Research Site, Berlin
Research Site, Amherst
Research Site, Philadelphia
Research Site, Turku
Research Site, Hamburg
Research Site, Pikesville
Research Site, Virginia Beach
Research Site, Kiel
Research Site, Greensboro
Research Site, Decatur
Research Site, Atlanta
Research Site, Jacksonville
Research Site, Orlando
Research Site, Tampere
Research Site, West Palm Beach
Research Site, Palm Beach Gardens
Research Site, Nashville
Research Site, Cleveland
Research Site, Bochum
Research Site, Essen
Research Site, Indianapolis
Research Site, Ann Arbor
Research Site, St Louis
Research Site, Springfield
Research Site, Dallas
Research Site, Dallas
Research Site, Austin
Research Site, Reno
Research Site, Oulu
Research Site, Santa Monica
Research Site, Sherman Oaks
Research Site, Newport Beach
Research Site, Palo Alto
Research Site, Seattle
Research Site, Stamford
Research Site, Watertown
Research Site, Worcester
Research Site, Calgary
Research Site, Montreal
Research Site, Brno
Research Site, Brno
Research Site, Prague
Research Site, Prague
Research Site, Helsinki
Research Site, Krakow
Research Site, Lodz
Research Site, Lublin
Research Site, Poznan
Research Site, Świdnik
Research Site, Warsaw
Research Site, Falköping
Research Site, Stockholm
Research Site, Stockholm
Research Site, Stockholm
Research Site, Vällingby
Research Site, Glasgow
Research Site, Hull
Research Site, London
Research Site, Stoke-on-Trent
Lead Sponsor
Amgen
INDUSTRY